Trade
Basic
Futures
Futures
Hundreds of contracts settled in USDT or BTC
Options
HOT
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
NEW
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
NEW
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
NEW
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
Kehua Holdings: The controlling shareholder plans to transfer shares, and the stock will be suspended next Monday.
2025-08-15 09:16
After reviewing 35 years of A-share trends, what will happen after the Shanghai Composite Index reaches a ten-year high?
2025-08-15 08:49
Trending Topics
View More5.69K Popularity
17.88K Popularity
13.1K Popularity
6.41K Popularity
94.47K Popularity
Hot Gate Fun
View More- MC:$3.65KHolders:20.47%
- MC:$3.6KHolders:10.00%
- MC:$3.62KHolders:20.00%
- MC:$4.18KHolders:22.78%
- MC:$3.61KHolders:20.00%
Pin
Gate Square New & Returning Creator Rewards are ongoing!
Your ideas may be more valuable than you think!
Make your first post or come back post to share a $20,000 monthly prize pool!
Post with #MyFirstPostOnSquare to receive a $50 Position Voucher each
Monthly Top Posters and Top Engagers will each earn an extra $50 reward
Your crypto insights could inspire many—start creating today!
👉 https://www.gate.com/postGate Square “Creator Certification Incentive Program” — Recruiting Outstanding Creators!
Join now, share quality content, and compete for over $10,000 in monthly rewards.
How to Apply:
1️⃣ Open the App → Tap [Square] at the bottom → Click your [avatar] in the top right.
2️⃣ Tap [Get Certified], submit your application, and wait for approval.
Apply Now: https://www.gate.com/questionnaire/7159
Token rewards, exclusive Gate merch, and traffic exposure await you!
Details: https://www.gate.com/announcements/article/47889Your First Words Matter!
Share your first post on and split $10,000 in New Year rewards.
Post with #My2026FirstPost to share your New Year wish
2026U Position Voucher, Gate New Year boxes, F1 Red Bull merch await you!
Ends on Jan 15, 2026, 16:00 UTC
2026 starts with this post!Gate 2025 Year-End Gala Square TOP50 List Announced!
The final ranking phase is now live.
Earn Votes by watching live streams and posting.
30 Votes = 1 chance — support your favorite creators now!
👉 https://www.gate.com/activities/community-vote-2025
iPhone 17 Pro Max, JD gift cards, Mi Band, Gate merch await you!
Creators are welcome to rally fans to climb the rankings and win rewards!
Voting ends: Jan 20, 02:00 UTC
Details: https://www.gate.com/announcements/article/48693
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.